全球汞中毒治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計汞中毒治療市場將從 2025 年的 19 億美元成長到 2034 年的 33.4 億美元，2026 年至 2034 年的複合年成長率為 6.47%。

由於人們對重金屬毒性和健康影響的認知不斷提高，全球汞中毒治療市場正穩步成長。接觸汞（通常由工業活動、受污染的食物和環境污染引起）會導致嚴重的神經系統和全身性損傷。這推動了全球對有效診斷和治療方案的需求。

主要促進因素包括工業化進程的推進、環境監測的加強以及公眾健康意識的提高。螯合療法仍然是主要的治療方法之一，這得益於診斷技術的進步，使得汞中毒的早期檢測成為可能。此外，各國政府和醫療機構為遏制汞暴露而實施的更嚴格的法規也促進了市場成長。

隨著治療方法的進步和醫療基礎設施的改善，預計未來市場將持續成長。對更安全、更有效的螯合劑的研究將有助於改善治療效果。此外，人們日益關注環境永續性和污染防治，這將有助於減少汞暴露，並在支撐治療方案的需求方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球汞中毒治療市場：依形式分類

• 市場分析、洞察與預測
• 甲基汞
• 元素汞
• 其他

第5章 全球汞中毒治療市場：依疾病分類

• 市場分析、洞察與預測
• 急性汞中毒
• 慢性汞中毒

第6章：全球汞中毒治療市場：依藥物分類

• 市場分析、洞察與預測
• 二巰基丙醇
• 二巰基琥珀酸酯
• D-Penicillamine
• 其他

第7章：全球汞中毒治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 注射藥物
• 口服

第8章 全球汞中毒治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 居家照護
• 專科診所
• 其他

第9章：全球汞中毒治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 網路藥房
• 零售商
• 其他

第10章 全球汞中毒治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • GlaxoSmithKline Plc
  • Teva Pharmaceutical Industries Ltd
  • EmeraMed Limited
  • Mylan NV
  • Akorn Incorporated
  • Sanofi
  • Heyl Chemisch-pharmazeutische Fabrik GmbH Co. KG
  • Genex Pharma
  • Recordati SpA
  • Pfizer Inc
  • Novartis AG
  • Merck & Co.Inc
  • Johnson & Johnson
  • AstraZeneca Plc
  • Bayer AG
  • Eli Lilly And Company

The Mercury Poisoning Treatment Market size is expected to reach USD 3.34 Billion in 2034 from USD 1.90 Billion (2025) growing at a CAGR of 6.47% during 2026-2034.

The global mercury poisoning treatment market is growing steadily due to increasing awareness about heavy metal toxicity and its health impacts. Mercury exposure, often caused by industrial activities, contaminated food, and environmental pollution, can lead to severe neurological and systemic disorders. This has led to a rising demand for effective diagnostic and treatment solutions worldwide.

Key drivers include growing industrialization, increased environmental monitoring, and rising healthcare awareness. Chelation therapy remains the primary treatment method, supported by advancements in diagnostic technologies that enable early detection of mercury toxicity. Governments and health organizations are also implementing stricter regulations to control mercury exposure, further influencing market growth.

Looking ahead, the market is expected to expand with advancements in treatment methods and improved healthcare infrastructure. Research into safer and more effective chelating agents will enhance therapeutic outcomes. Increasing focus on environmental sustainability and pollution control will also play a crucial role in reducing mercury exposure while supporting the demand for treatment solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Forms

• Methylmercury
• Elemental Mercury
• Others

By Disease

• Acute Mercury Poisoning
• Chronic Mercury Poisoning

By Drugs

• Dimercaprol
• Dimercaptosuccinic Acid
• D-Pennicillamine
• Others

By Route of Administration

• Injectable
• Oral

By End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retailers
• Others

COMPANIES PROFILED

• GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, EmeraMed Limited, Mylan NV, Akorn Incorporated, Sanofi, Heyl Chemischpharmazeutische Fabrik GmbH Co KG, Genex Pharma, Recordati SpA, Pfizer Inc, Novartis AG, Merck Co, Inc, Johnson Johnson, AstraZeneca plc, Bayer AG, Eli Lilly and Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MERCURY POISONING TREATMENT MARKET: BY FORMS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Forms
• 4.2. Methylmercury Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Elemental Mercury Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MERCURY POISONING TREATMENT MARKET: BY DISEASE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease
• 5.2. Acute Mercury Poisoning Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Chronic Mercury Poisoning Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MERCURY POISONING TREATMENT MARKET: BY DRUGS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drugs
• 6.2. Dimercaprol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Dimercaptosuccinic Acid Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. D-Pennicillamine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MERCURY POISONING TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MERCURY POISONING TREATMENT MARKET: BY END USERS 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End Users
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL MERCURY POISONING TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Distribution Channel
• 9.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Retailers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL MERCURY POISONING TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Forms
  • 10.2.2 By Disease
  • 10.2.3 By Drugs
  • 10.2.4 By Route Of Administration
  • 10.2.5 By End Users
  • 10.2.6 By Distribution Channel
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Forms
  • 10.3.2 By Disease
  • 10.3.3 By Drugs
  • 10.3.4 By Route Of Administration
  • 10.3.5 By End Users
  • 10.3.6 By Distribution Channel
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Forms
  • 10.4.2 By Disease
  • 10.4.3 By Drugs
  • 10.4.4 By Route Of Administration
  • 10.4.5 By End Users
  • 10.4.6 By Distribution Channel
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Forms
  • 10.5.2 By Disease
  • 10.5.3 By Drugs
  • 10.5.4 By Route Of Administration
  • 10.5.5 By End Users
  • 10.5.6 By Distribution Channel
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Forms
  • 10.6.2 By Disease
  • 10.6.3 By Drugs
  • 10.6.4 By Route Of Administration
  • 10.6.5 By End Users
  • 10.6.6 By Distribution Channel
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL MERCURY POISONING TREATMENT INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 GlaxoSmithKline Plc
  • 12.2.2 Teva Pharmaceutical Industries Ltd
  • 12.2.3 EmeraMed Limited
  • 12.2.4 Mylan N.V
  • 12.2.5 Akorn Incorporated
  • 12.2.6 Sanofi
  • 12.2.7 Heyl Chemisch-pharmazeutische Fabrik GmbH Co. KG
  • 12.2.8 Genex Pharma
  • 12.2.9 Recordati S.p.A
  • 12.2.10 Pfizer Inc
  • 12.2.11 Novartis AG
  • 12.2.12 Merck & Co.Inc
  • 12.2.13 Johnson & Johnson
  • 12.2.14 AstraZeneca Plc
  • 12.2.15 Bayer AG
  • 12.2.16 Eli Lilly And Company